Search company, investor...
XTL Biopharmaceuticals company logo

XTL Biopharmaceuticals



Date of IPO


Market Cap


About XTL Biopharmaceuticals

XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

Headquarters Location

5 HaCharoshet St.

Ra'anana, 4365603,



Missing: XTL Biopharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: XTL Biopharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

XTL Biopharmaceuticals Patents

XTL Biopharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Monoclonal antibodies
  • Amines
patents chart

Application Date

Grant Date


Related Topics




Nitrogen heterocycles, Oxygen heterocycles, Indoles, Drug discovery, Pyrazoles


Application Date


Grant Date



Related Topics

Nitrogen heterocycles, Oxygen heterocycles, Indoles, Drug discovery, Pyrazoles



Latest XTL Biopharmaceuticals News


Aug 24, 2022

08/24/2022 | 10:58am EDT Message : AS OF JUNE 30, 2022 INDEX June 30, 220 172 EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: Share capital - ordinary shares of NIS 0.1 par value: authorized shares - 1,450,000,000 on June 30, 2022 and December 31, 2021; issued and outstanding: 544,906,149 on June 30, 2022 and December 31, 2021; 14,120 20 Approval date of the interim consolidated financial statements by the Company's Board: August 23, 2022. 2 Six months ended Research and development expenses 221 0.000 ) 544,906,149 3 Six months ended June 30, 2022 Share 14,120 - 14,120 Share 13,182 421 - 13,603 4 Six months ended Net income (loss) for the period 221 (841 (620 Interest income from bank deposit 8 8 Net cash provided by financing activities - (612 (11 2,969 2,346 5 Six months ended Income and expenses not involving operating cash flows: Depreciation 9 11 Increase in prepaid expenses and other current assets (110 (59 6 NOTE 1: A general description of the Company and its activity: XTL Biopharmaceuticals Ltd. (the "Company") is engaged in the development of therapeutics for the treatment of unmet medical needs of Systemic Lupus Erythematosus ("SLE"). In 2014, the Company signed a licensing agreement with Yeda, as amended on September 6, 2015, to develop hCDR1, a Phase II-ready asset for the treatment of SLE. The Company was incorporated under the Israeli Companies Law on March 9, 1993. The registered office of the Company is located at 5 Badner Street, Ramat Gan, Israel. The Company's American Depository Shares ("ADSs") are listed for trading on the Nasdaq Capital Market ("Nasdaq") and its ordinary shares are traded on the Tel-Aviv Stock Exchange ("TASE"). The Company has a wholly-owned subsidiary, Xtepo Ltd. ("Xtepo"), which was incorporated in Israel. The Company and Xtepo are heretofore referred to as the Group. NOTE 2: a. The condensed consolidated financial information of the Company as of June 30, 2022 and for the respective interim periods of six and three months then ended ("interim financial information") has been prepared in accordance with IAS 34, "Interim Financial Reporting" ("IAS 34"). This interim financial information does not contain all the information and disclosures that are required in the framework of the annual financial statements. This interim financial information should be read in conjunction with the annual financial statements for 2021 and the accompanying notes which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. b. Estimates - the preparation of the interim consolidated financial statements requires the Company's management to make judgments and to use accounting estimates and assumptions that have an effect on the application of the Company's accounting policies and on the reported amounts of assets, liabilities and expenses. Actual results could differ from those estimates. In the preparation of these interim consolidated financial statements, the significant judgment exercised by management in applying the Company's accounting policies and the uncertainties involved in the key sources of the estimates were identical to those in the annual consolidated financial statements for the year ended December 31, 2021. 7 NOTE 3: SIGNIFICANT ACCOUNTING POLICIES The Company's significant accounting policies and methods of computation adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual consolidated financial statements for 2021. NOTE 4: a. All marketable securities held by the Company constitute Level 1 financial instruments, as defined in IFRS 13 - "Fair Value Measurement". Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. b. June 30, 3,158 The entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of June 30, 2022 the Company holds approximately 1% of InterCure Ltd's shares (the shares are traded at the Tel-Aviv Stock Exchange - "TASE"). c. Changes in marketable securities for the six months ended June 30, 2022 and same period in 2021 were all from changes in the fair value (no sales occurred). During the six and three months ended June 30, 2022, the Company recorded finance expense at the amount of $348 thousands and $572 thousands, respectively, with respect of marketable securities revaluation. NOTE 5: WARRANT LIABILITY During the year ended December 31, 2017, the Company raised gross funds amounted to $5,300 thousand by issuance of 2,400,000 ADS's and 2,450,000 warrants to purchase the same amount of ADS's. The warrants shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The number of warrants and their exercise price could be adjusted upon standard anti-dilution protection clauses and subject to a cashless exercise mechanism. The Company accounted for the warrants issued to investors with a cashless exercise mechanism as a non-current liability according to provisions of IAS 32. The Company measured the warrants at fair value by using a Black and Scholes model. The warrants were measured in each reporting period. Changes in the fair value were recognized in the Company's statement of comprehensive income (loss) as financial income or expense, as appropriate. The warrants were classified as level 3. 8

XTL Biopharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

XTL Biopharmaceuticals Rank

XTL Biopharmaceuticals Frequently Asked Questions (FAQ)

  • Where is XTL Biopharmaceuticals's headquarters?

    XTL Biopharmaceuticals's headquarters is located at 5 HaCharoshet St., Ra'anana.

  • What is XTL Biopharmaceuticals's latest funding round?

    XTL Biopharmaceuticals's latest funding round is IPO.

  • Who are the investors of XTL Biopharmaceuticals?

    Investors of XTL Biopharmaceuticals include The Challenge Fund-Etgar and Israel Healthcare Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.